{
    "clinical_study": {
        "@rank": "55307", 
        "acronym": "TWICS", 
        "arm_group": [
            {
                "arm_group_label": "hypertonic saline", 
                "arm_group_type": "Experimental", 
                "description": "inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group).  Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff.  Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes)."
            }, 
            {
                "arm_group_label": "saline", 
                "arm_group_type": "Active Comparator", 
                "description": "inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group).  Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff.  Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes)."
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis: substitution of nebulized 3% NaCl (HS) for the standard normal saline (NS) used\n      in bronchodilator therapy for acute viral wheezing in all children under age 6 years will\n      provide superior symptom relief leading to decreased admission rates from the Emergency\n      Department.\n\n      The study will test the efficacy of frequent doses of inhaled bronchodilator co-administered\n      with either 3% hypertonic saline (HS, study group) or 0.9% normal saline (NS, control group)\n      in a prospective, double blind, randomized controlled, multi-centre clinical trial of\n      children under age 6 years presenting to the ED with acute viral-associated wheezing."
        }, 
        "brief_title": "Treating Wheezing in Children With Hypertonic Saline (TWICS)", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Wheeze", 
        "detailed_description": {
            "textblock": "the brief summary captures the essence of the study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age under 6 years\n\n          2. History of viral upper respiratory infection within previous 7 days\n\n          3. Wheezing or crackles detected on chest auscultation\n\n          4. Respiratory Distress Assessment Instrument (RDAI) score of 4 or greater or oxygen\n             saturation (SaO2) of 94% or less in room air.\n\n        Exclusion Criteria:\n\n          1. History of immunodeficiency, chronic cardiopulmonary disease (other than past history\n             of wheezing), Down syndrome, gestational age under 34 weeks.\n\n          2. Severe illness at presentation as defined by any of the following\n\n               -  respiratory rate greater than 80/min\n\n               -  SaO2 less than 88% in room air\n\n               -  need for assisted ventilation\n\n          3. Use of nebulized HS within previous 12 hours\n\n          4. Presence of active varicella infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868932", 
            "org_study_id": "TWICS", 
            "secondary_id": "HSTWICS"
        }, 
        "intervention": [
            {
                "arm_group_label": "hypertonic saline", 
                "description": "inhaled nebulized 3%NaCl", 
                "intervention_name": "hypertonic saline", 
                "intervention_type": "Other", 
                "other_name": [
                    "nebulized hypertonic saline", 
                    "aerosolized hypertonic saline"
                ]
            }, 
            {
                "arm_group_label": "saline", 
                "description": "inhaled nebulized 0.9% NaCl", 
                "intervention_name": "saline", 
                "intervention_type": "Other", 
                "other_name": [
                    "nebulized saline", 
                    "aerosolized saline"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "wheeze", 
            "early childhood", 
            "asthma", 
            "bronchiolitis", 
            "infection triggered"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treating Wheezing in Children With Hypertonic Saline (TWICS)", 
        "overall_official": {
            "affiliation": "Queen's University", 
            "last_name": "Michael Flavin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rates of admission to hospital", 
            "measure": "Rates of admission to hospital", 
            "safety_issue": "No", 
            "time_frame": "duration of hospital ER stay, an average of 4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868932"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Queen's University", 
            "investigator_full_name": "Michael Flavin", 
            "investigator_title": "Professor of Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement in respiratory distress scores after initial protocol treatment in the ED", 
                "measure": "Improvement in respiratory distress scores after initial protocol treatment in the ED", 
                "safety_issue": "No", 
                "time_frame": "time from pre-intervention assessment to post-intervention assessment, an average of 2 hours"
            }, 
            {
                "description": "Length-of-stay in the ED in the subgroup of patients not admitted", 
                "measure": "Length-of-stay in the ED in the subgroup of patients not admitted", 
                "safety_issue": "No", 
                "time_frame": "an average of 6 hours"
            }, 
            {
                "description": "Cumulative dose of bronchodilator administered in ED prior to admission/discharge order", 
                "measure": "Cumulative dose of bronchodilator administered in ED prior to admission/discharge order", 
                "safety_issue": "No", 
                "time_frame": "an average of 6 hours"
            }, 
            {
                "description": "Length of hospital stay in the those who are admitted", 
                "measure": "Length of hospital stay in the those who are admitted", 
                "safety_issue": "No", 
                "time_frame": "length of hospital stay, an average of 3 days"
            }, 
            {
                "description": "Rate of return visit to ED (for respiratory illness) within 14 days of enrollment", 
                "measure": "Rate of return visit to ED (for respiratory illness) within 14 days of enrollment", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Queen's University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Michael Flavin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Funding declined. Study never initiated."
    }
}